Deciphera Pharmaceuticals, Inc.
DCPHNext catalyst
Tirabrutinib
relapsed or refractory PCNSL
Get an email about DCPH's next catalysts
Track Deciphera Pharmaceuticals (DCPH) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (Phase 2 readout).See the timeline
3 upcoming, 0 past
FDA PDUFA Date Tirabrutinib
For relapsed or refractory PCNSL. NDA accepted. AI-extracted from: Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance
SourceInlexisertib Phase 2 Est. Readout
Estimated primary completion for Inlexisertib trial (NCT05957367) in GIST. Topline data typically follows completion by weeks to months.
SourceInlexisertib Phase 2 Est. Readout
Primary completion for Inlexisertib trial (NCT04892017) in Non-Small Cell Lung Cancer
SourceMarket Overview
Stock performance and key metrics
Ripretinib
GIST
Vimseltinib
Chronic Graft-Versus-Host Disease (cGVHD)
DCC-2618
Gastrointestinal Stromal Tumors
Sapablursen
Polycythemia Vera
Tirabrutinib
Relapsed/Refractory Primary Central Nervous System Lymphoma
Sunitinib
Gastrointestinal Stromal Tumors
DCC-3084
Advanced Solid Tumor
DCC-3009
Gastrointestinal Stromal Tumor (GIST)
Inlexisertib
Non-Small Cell Lung Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ripretinib | Phase 3 | GIST | - | - |
Vimseltinib | Phase 3 | Chronic Graft-Versus-Host Disease (cGVHD) | - | - |
DCC-2618 | Phase 3 | Gastrointestinal Stromal Tumors | - | - |
Sapablursen | Phase 3 | Polycythemia Vera | - | - |
Tirabrutinib | Phase 3 | Relapsed/Refractory Primary Central Nervous System Lymphoma | - | - |
Sunitinib | Phase 3 | Gastrointestinal Stromal Tumors | - | - |
DCC-3084 | Phase 2 | Advanced Solid Tumor | - | - |
DCC-3009 | Phase 2 | Gastrointestinal Stromal Tumor (GIST) | - | - |
Inlexisertib | Phase 2 | Non-Small Cell Lung Cancer | - | - |
Frequently asked questions
What is in Deciphera Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 9 drug candidates in Deciphera Pharmaceuticals, Inc.'s (DCPH) pipeline across Phase 3, Phase 2. Its lead program is Tirabrutinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Deciphera Pharmaceuticals, Inc.'s next FDA catalyst?→
Deciphera Pharmaceuticals, Inc.'s (DCPH) next tracked catalyst is a PDUFA date expected February 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track DCPH biotech catalysts?→
Add DCPH to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Deciphera Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.